期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 12, 期 3, 页码 435-441出版社
INFORMA HEALTHCARE
DOI: 10.1517/14656566.2011.521153
关键词
-
Areas covered: Published studies on pharmacoeconomics of warfarin pharmacogenomic application are reviewed. A literature search was done using Medline and Embase covering the period 2000 -- 2010. Decision tree and Markov modeling were the most frequently used methods in the reviewed reports. Studies incorporating clinical efficacy data of genotype-guided dosing algorithm had shown that warfarin pharmacogenomics would improve quality-adjusted life-years (QALYs) gained. Nevertheless, it was unlikely to be cost-effective for general patients. Influential factors to improve the cost-effectiveness included low genotyping cost, high effectiveness in improving anticoagulation control/event rate, and applying warfarin pharmacogenomics to patients with high bleeding risk or at practice sites with suboptimal management of anticoagulation control. Expert opinion: Warfarin pharmacogenomics would improve QALYs and could possibly be cost-effective in selected patient groups or practice sites.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据